Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

The causes and consequences of overactive bladder.

Miller J, Hoffman E.

J Womens Health (Larchmt). 2006 Apr;15(3):251-60. Review.

PMID:
16620184
2.

Muscarinic receptor antagonists for overactive bladder.

Abrams P, Andersson KE.

BJU Int. 2007 Nov;100(5):987-1006. Review.

3.

Overactive bladder treatments in early phase clinical trials.

Colli E, Digesu GA, Olivieri L.

Expert Opin Investig Drugs. 2007 Jul;16(7):999-1007. Review.

PMID:
17594185
4.
5.

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.

Wagg A, Wyndaele JJ, Sieber P.

Am J Geriatr Pharmacother. 2006 Mar;4(1):14-24.

PMID:
16730617
6.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
7.

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

Garely AD, Lucente V, Vapnek J, Smith N.

Ann Pharmacother. 2007 Mar;41(3):391-8. Epub 2007 Mar 6.

PMID:
17341526
8.

Perceptions and behaviours of women with bladder control problems.

Diokno AC, Sand PK, Macdiarmid S, Shah R, Armstrong RB.

Fam Pract. 2006 Oct;23(5):568-77. Epub 2006 May 26.

PMID:
16731545
9.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
10.

Management of overactive bladder and urge urinary incontinence in the elderly patient.

Erdem N, Chu FM.

Am J Med. 2006 Mar;119(3 Suppl 1):29-36. Review.

PMID:
16483866
11.

Health-related consequences of overactive bladder.

Wagner TH, Hu TW, Bentkover J, LeBlanc K, Stewart W, Corey R, Zhou Z, Hunt T.

Am J Manag Care. 2002 Dec;8(19 Suppl):S598-607.

12.

Agents for treatment of overactive bladder: a therapeutic class review.

Hesch K.

Proc (Bayl Univ Med Cent). 2007 Jul;20(3):307-14.

13.

Understanding the elements of overactive bladder: questions raised by the EPIC study.

Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K; EPIC Study Group.

BJU Int. 2008 Jun;101(11):1381-7. doi: 10.1111/j.1464-410X.2008.07573.x. Epub 2008 Mar 10.

14.

The wet patient: understanding patients with overactive bladder and incontinence.

Serels S.

Curr Med Res Opin. 2004 Jun;20(6):791-801. Review.

PMID:
15200735
15.
16.

Role of muscarinic receptor antagonists in urgency and nocturia.

Michel MC, de la Rosette JJ.

BJU Int. 2005 Sep;96 Suppl 1:37-42. Review.

17.

What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy?

Van Brummen HJ, Bruinse HW, Van de Pol G, Heintz AP, Van der Vaart CH.

BJU Int. 2006 Feb;97(2):296-300.

18.

Overactive bladder--a practical approach to evaluation and management.

Madersbacher H.

J Med Liban. 2004 Oct-Dec;52(4):220-6. Review.

PMID:
16432986
19.
20.

Pathophysiology of overactive bladder.

Chu FM, Dmochowski R.

Am J Med. 2006 Mar;119(3 Suppl 1):3-8. Review.

PMID:
16483862

Supplemental Content

Support Center